Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MR Clear all
Completed Not applicable Interventional

Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children

NCT02349971
View directory record Official record
Conditions
Osteoid Osteoma
Interventions
MR-HIFU
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Phase 1 Interventional

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Valued EpiGenetic Glycemic ImprovEments Through Weight Loss

NCT02869659
View directory record Official record
Conditions
Obesity, Pre-diabetes
Interventions
Weight Loss Group, Delayed Weight Loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 23, 2026, 6:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phono- and Electrocardiogram Assisted Detection of Valvular Disease

NCT03458806
View directory record Official record
Conditions
Aortic Valve Stenosis, Mitral Regurgitation, Heart Murmurs, Valvular Heart Disease
Interventions
AS Algorithm 1, AS Algorithm 2, MR Algorithm 1, MR Algorithm 2
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Early Phase 1 Interventional

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT07089940
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed No phase listed Observational

Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions

NCT00527891
View directory record Official record
Conditions
Liver Cancer
Interventions
Signa Excite 3.0 T MRI Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

NCT03604978
View directory record Official record
Conditions
Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions
Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

NCT07225985
View directory record Official record
Conditions
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

NCT02006108
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Feraheme, MRI-GE Healthcare 3 Tesla magnet
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 23, 2026, 6:21 PM EDT
Withdrawn Phase 2 Interventional

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100
View directory record Official record
Conditions
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Early Phase 1 Interventional

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02079740
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Phase 1 Interventional

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT06130826
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

NCT04826185
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
IMB-1018972, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 23, 2026, 6:21 PM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 6:21 PM EDT
Withdrawn No phase listed Observational

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

NCT01973517
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 23, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

NCT00518466
View directory record Official record
Conditions
Obesity
Interventions
topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 6:21 PM EDT
Active, not recruiting Not applicable Interventional

Diffusion MRI for Head and Neck Cancer

NCT04251481
View directory record Official record
Conditions
Head Cancer Neck
Interventions
PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 23, 2026, 6:21 PM EDT